Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19584759 | 0.77 | F2RL1 (0.46) | F2RL1 | |
| SCHEMBL19584667 | 0.74 | F2RL1 (0.33) | F2RL1 | |
| SCHEMBL5987345 | 0.72 | ALDH2 (0.37) | F2RL1ALDH2KCNA3 | |
| SCHEMBL16004961 | 0.72 | ALDH2 (0.33) | F2RL1ALDH2KCNA3 | |
| SCHEMBL19584621 | 0.70 | F2RL1 (0.48) | F2RL1 | |
| SCHEMBL24946163 | 0.69 | ALDH1A1 (0.39) | — | |
| SCHEMBL6305348 | 0.69 | KCNA3 (0.39) | F2RL1CES1KCNA3 | |
| SCHEMBL6304529 | 0.67 | ALDH2 (0.32) | ALDH2 | |
| SCHEMBL20356119 | 0.66 | KDM1A (0.32) | — | |
| SCHEMBL289277 | 0.64 | ACHE (0.39) | F2RL1CES1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3455212-B1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LTD (GB) | 2022-02-09 | — | — | EP | disclosed |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | NXERA PHARMA UK LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3455212-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | Heptares Therapeutics Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | F2RL1 1/4885CES1 818/4885ALDH2 3783/4885 |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | F2RL1 1/4885CES1 818/4885ALDH2 3783/4885 |
| US-10995072-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | F2RL1 1/4885CES1 1713/4885ALDH2 2662/4885 |
| US-20200140392-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | F2RL1 1/4885CES1 1713/4885ALDH2 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.